Mohamed Elgazzar | Associate Professor
VA Building # 1
Graduate: PhD, Molecular Immunology, Kumamoto University, Japan, 2002
Fellowships: Research Associate, Dept. of Pediatrics, National Jewish Medical and Research Center Denver, CO 2003-2004; Research Associate, Dept. of Medicine, University of Colorado Health Sciences Center, Denver, CO 2004-2006; Research Fellow, Dept. of Internal Medicine, Section on Molecular Medicine, Wake Forest University School of Medicine, Winston Salem, NC 2006-2007
Special Areas of Interest: Innate immunity; Myeloid cell reprogramming; MicroRNAs in severe systemic inflammation.
Mohamed Elgazzar, PhD, is a Molecular Immunologist and an Associate Professor. He Received his PhD in 2002 from Kumamoto University School of Medicine, Japan. He received his postdoctoral training in Immunology at the National Jewish Medical Center and University of Colorado in Denver and in Infectious Diseases at Wake Forest University School of Medicine in Winston-Salem before joining ETSU. He holds an adjunct assistant professor position in the Department of Biomedical Sciences. He has authored over 36 original research and review manuscripts.
As a Molecular Immunologist with broad-based training in immunology and infectious diseases, Dr. Elgazzar's laboratory research focuses on basic molecular processes that can be translated to the field of inflammation, with a focus on severe systemic inflammatory processes like sepsis. His specific contributions and emphasis are on epigenetic and microRNA based regulation that generates reprogramming of genes linked to inflammation. His recent work indicates that microRNAs play a role in sepsis pathogenesis, including immunosuppression and chronic inflammation, a poorly understood and highly prevalent aspect of sepsis that increases rates of mortality to infection or injury. His work is at the forefront of sepsis research, having developed a mouse model of sepsis that can be followed over an extended period of time and that allows for manipulating the late immunosuppressive state of sepsis. His laboratory is currently funded by 2 NIH grants. He collaborates with researchers at ETSU, Wake Forest University, and University of Pennsylvania.